Mathieu Simonin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mathieu Simonin has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
- Vahid Asnafi
Laboratory of Onco-Hematology, Necker Children’s Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
24 shared publications - Nicolas Boissel
Hôpital Saint-Louis, AP-HP, Paris, France
23 shared publications - Elizabeth Macintyre
University Paris Cité and Assistance Publique-Hôpitaux de Paris, AP-HP Centre, Paris, France
22 shared publications - Guillaume P. Andrieu
Institut Necker-Enfants Malades
22 shared publications - Aurore Touzart
Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany
20 shared publications - Philippe Rousselot
26Department of Hematology, Centre Hospitalier de Versailles, Le Chesnay Rocquencourt, France
20 shared publications
Latest Publications
- Open Access
- 19 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Anti-thymocyte globulin triggers TNF-dependent cell death in T-cell acute lymphoblastic leukemia
T-cell acute lymphoblastic leukemia (T-ALL) accounts for one of the most aggressive hematological tumors associated with poor prognosis, notably for relapsed and refractory patients. Hence, an unmet medical need persists for T-ALL patients who fail to durably respond to conventional treatments. Herein, we report the antileukemic efficacy of anti-thymocyte globulin (ATG), a polyclonal cocktail of IgG enriched in antibodies directed against human thymocyte antigens. The treatment of preclinical models of T-ALL reveals a cytotoxic mechanism of ATG mediated by TNFα signaling. We demonstrate that ATG resistance may occur via the induction of negative regulators of TNFα-induced cell death and can be circumvented by SMAC mimetic birinapant ex vivo and in vivo. These results are validated in a series of prospective primary relapsed/refractory T-ALL samples. Here, we provide a strong rationale for clinically relevant ATG-based immunotherapy in combination with birinapant to treat T-ALL patients.
- 19 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAnti-thymocyte globulin triggers TNF-dependent cell death in T-cell acute lymphoblastic leukemia
T-cell acute lymphoblastic leukemia (T-ALL) accounts for one of the most aggressive hematological tumors associated with poor prognosis, notably for relapsed and refractory patients. Hence, an unmet medical need persists for T-ALL patients who fail to durably respond to conventional treatments. Herein, we report the antileukemic efficacy of anti-thymocyte globulin (ATG), a polyclonal cocktail of IgG enriched in antibodies directed against human thymocyte antigens. The treatment of preclinical models of T-ALL reveals a cytotoxic mechanism of ATG mediated by TNFα signaling. We demonstrate that ATG resistance may occur via the induction of negative regulators of TNFα-induced cell death and can be circumvented by SMAC mimetic birinapant ex vivo and in vivo. These results are validated in a series of prospective primary relapsed/refractory T-ALL samples. Here, we provide a strong rationale for clinically relevant ATG-based immunotherapy in combination with birinapant to treat T-ALL patients.
- Open Access
- 20 April 2026
- Published by Wiley in HemaSphere
- Vol. 10 (4)
Integration of circulating tumor DNA profiling in the risk stratification of classical Hodgkin lymphoma in children, adolescents, and young adults
This study aimed to define the potential role of circulating tumor DNA (ctDNA) in children, adolescents, and young adults (CAYA) with classical Hodgkin lymphoma (cHL). This prospective trial was conducted in France between 2019 and 2023 and recruited CAYA patients (≤25 years old) with a new diagnosis of cHL. Patients were treated according to the EuroNet‐PHL‐C2 trial (EudraCT: 2012‐004053‐88), and plasma ctDNA evaluations were performed at diagnosis, after two cycles of chemotherapy, and in case of relapse. Two hundred and seventy‐five patients were included. Median age at diagnosis was 15 years (range 2–22), and 47% of the patients were treated as advanced stages (treatment level 3 [TL‐3]). Using an 18‐gene amplicon‐based next‐generation sequencing (NGS) targeted panel encompassing the most frequently mutated genes in cHL, at least one mutation was detected in 236/275 patients (86%). B‐symptoms, erythrocyte sedimentation rate, and advanced stages were significantly associated with the level of ctDNA at diagnosis. TP53 mutations (19/275, 7%) were strongly associated with inadequate response at early response assessment. XPO1 and IGLL5 mutations were associated with a higher risk of relapse. The presence of detectable ctDNA after two cycles of chemotherapy (10%) was a strong and independent prognostic marker of relapse.
- 20 April 2026
- Published by Wiley in HemaSphere
- Vol. 10 (4)
Open AccessIntegration of circulating tumor DNA profiling in the risk stratification of classical Hodgkin lymphoma in children, adolescents, and young adults
This study aimed to define the potential role of circulating tumor DNA (ctDNA) in children, adolescents, and young adults (CAYA) with classical Hodgkin lymphoma (cHL). This prospective trial was conducted in France between 2019 and 2023 and recruited CAYA patients (≤25 years old) with a new diagnosis of cHL. Patients were treated according to the EuroNet‐PHL‐C2 trial (EudraCT: 2012‐004053‐88), and plasma ctDNA evaluations were performed at diagnosis, after two cycles of chemotherapy, and in case of relapse. Two hundred and seventy‐five patients were included. Median age at diagnosis was 15 years (range 2–22), and 47% of the patients were treated as advanced stages (treatment level 3 [TL‐3]). Using an 18‐gene amplicon‐based next‐generation sequencing (NGS) targeted panel encompassing the most frequently mutated genes in cHL, at least one mutation was detected in 236/275 patients (86%). B‐symptoms, erythrocyte sedimentation rate, and advanced stages were significantly associated with the level of ctDNA at diagnosis. TP53 mutations (19/275, 7%) were strongly associated with inadequate response at early response assessment. XPO1 and IGLL5 mutations were associated with a higher risk of relapse. The presence of detectable ctDNA after two cycles of chemotherapy (10%) was a strong and independent prognostic marker of relapse.
- Open Access
- 17 February 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (4) , 1331-1338
Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real‐world study
Summary: Classical Hodgkin lymphoma (cHL) is the most frequent lymphoma in children, adolescents and young adults (CAYA). Despite therapeutic advances, around 15% of patients relapse or have refractory (R/R) disease. Conventional salvage regimens remain effective but are associated with substantial long‐term toxicity. Immune checkpoint inhibitors (CPIs), such as nivolumab and pembrolizumab, and the anti‐CD30 antibody‐drug conjugate brentuximab vedotin (BV) have recently demonstrated encouraging efficacy with improved safety. We conducted a retrospective, multicentre nationwide study to assess the real‐world efficacy of CPI in CAYA patients (<18 years) with R/R cHL treated outside clinical trials in France between August 2015 and May 2023. Twenty‐seven patients from 11 centres were included. Median age at CPI initiation was 16 years; 70% had advanced disease. Prior treatments included BV (44%), autologous stem cell transplantation (22%) and allogeneic transplantation (4%). Nivolumab was used in 89%, frequently combined with BV (67%). The overall response rate was 93%, with 63% achieving complete metabolic response. After a median follow‐up of 28 months, 3‐year progression‐free survival and overall survival were 48% and 95%, respectively, and toxicities were manageable. These findings strongly support CPI as a highly effective and well‐tolerated treatment option for the CAYA population with R/R cHL even in heavily pretreated patients.
- 17 February 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (4) , 1331-1338
Open AccessEfficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real‐world study
Summary: Classical Hodgkin lymphoma (cHL) is the most frequent lymphoma in children, adolescents and young adults (CAYA). Despite therapeutic advances, around 15% of patients relapse or have refractory (R/R) disease. Conventional salvage regimens remain effective but are associated with substantial long‐term toxicity. Immune checkpoint inhibitors (CPIs), such as nivolumab and pembrolizumab, and the anti‐CD30 antibody‐drug conjugate brentuximab vedotin (BV) have recently demonstrated encouraging efficacy with improved safety. We conducted a retrospective, multicentre nationwide study to assess the real‐world efficacy of CPI in CAYA patients (<18 years) with R/R cHL treated outside clinical trials in France between August 2015 and May 2023. Twenty‐seven patients from 11 centres were included. Median age at CPI initiation was 16 years; 70% had advanced disease. Prior treatments included BV (44%), autologous stem cell transplantation (22%) and allogeneic transplantation (4%). Nivolumab was used in 89%, frequently combined with BV (67%). The overall response rate was 93%, with 63% achieving complete metabolic response. After a median follow‐up of 28 months, 3‐year progression‐free survival and overall survival were 48% and 95%, respectively, and toxicities were manageable. These findings strongly support CPI as a highly effective and well‐tolerated treatment option for the CAYA population with R/R cHL even in heavily pretreated patients.
- Open Access
- 28 December 2025
- Published by Wiley in HemaSphere
- Vol. 9 (12)
TLX1 translocation variants and enhancer hijacking influence clinical outcome in T‐cell acute lymphoblastic leukemia
The T‐cell Leukemia Homeobox 1 ( TLX1 ) oncogene is frequently deregulated in T‐cell acute lymphoblastic leukemia (T‐ALL) and T‐cell lymphoblastic lymphoma (T‐LBL). In most instances, TLX1 overexpression results from its juxtaposition with a T‐cell receptor ( TCR ) locus caused by interchromosomal translocations. However, in the subset of non‐ TCR ‐translocated TLX1 ‐positive (non‐ TCR TLX1 +) T‐ALL cases, the underlying mechanisms driving TLX1 overexpression and their clinico‐biological implications remain unclear. By integrating high‐resolution data from next‐generation sequencing, fluorescence in situ hybridization, karyotyping, optical genome mapping, and long‐read whole‐genome sequencing across a cohort of 1122 adult and pediatric T‐ALL/T‐LBL cases, we identified TLX1 overexpression in 11% of T‐ALL/T‐LBL cases, with an unexpected 14% incidence of non‐ TCR TLX1 + cases among TLX1 + cases. Non‐ TCR TLX1 + T‐ALL cases show distinct clinico‐biological features, including a lower frequency of cortical phenotype compared to the TCR ‐translocated TLX1 + ( TCR TLX1 +) subgroup, regardless of TLX1 expression levels. In non‐ TCR TLX1 ⁺ cases, TLX1 deregulation results mostly (83%) from the hijacking of the ANKRD1 and PCGF5 enhancer at 10q23.31 through various chromosomal aberrations. Genomic analyses revealed that these aberrations juxtapose the ANKRD1 and PCGF5 enhancer with TLX1 , driving its overexpression. Importantly, survival analysis revealed that non‐ TCR TLX1 + patients had significantly poorer outcomes compared to their TCR TLX1 ⁺ counterparts (3y‐OS: 55% vs. 90%, P < 0.001 and 3y‐DFS: 45% vs. 75%, P = 0.02). These findings, consistent with our previous observations in TAL1 ‐driven T‐ALL, confirm that the clinico‐biological impact of an oncogene is influenced by the specific mechanism underlying its deregulation.
- 28 December 2025
- Published by Wiley in HemaSphere
- Vol. 9 (12)
Open AccessTLX1 translocation variants and enhancer hijacking influence clinical outcome in T‐cell acute lymphoblastic leukemia
The T‐cell Leukemia Homeobox 1 ( TLX1 ) oncogene is frequently deregulated in T‐cell acute lymphoblastic leukemia (T‐ALL) and T‐cell lymphoblastic lymphoma (T‐LBL). In most instances, TLX1 overexpression results from its juxtaposition with a T‐cell receptor ( TCR ) locus caused by interchromosomal translocations. However, in the subset of non‐ TCR ‐translocated TLX1 ‐positive (non‐ TCR TLX1 +) T‐ALL cases, the underlying mechanisms driving TLX1 overexpression and their clinico‐biological implications remain unclear. By integrating high‐resolution data from next‐generation sequencing, fluorescence in situ hybridization, karyotyping, optical genome mapping, and long‐read whole‐genome sequencing across a cohort of 1122 adult and pediatric T‐ALL/T‐LBL cases, we identified TLX1 overexpression in 11% of T‐ALL/T‐LBL cases, with an unexpected 14% incidence of non‐ TCR TLX1 + cases among TLX1 + cases. Non‐ TCR TLX1 + T‐ALL cases show distinct clinico‐biological features, including a lower frequency of cortical phenotype compared to the TCR ‐translocated TLX1 + ( TCR TLX1 +) subgroup, regardless of TLX1 expression levels. In non‐ TCR TLX1 ⁺ cases, TLX1 deregulation results mostly (83%) from the hijacking of the ANKRD1 and PCGF5 enhancer at 10q23.31 through various chromosomal aberrations. Genomic analyses revealed that these aberrations juxtapose the ANKRD1 and PCGF5 enhancer with TLX1 , driving its overexpression. Importantly, survival analysis revealed that non‐ TCR TLX1 + patients had significantly poorer outcomes compared to their TCR TLX1 ⁺ counterparts (3y‐OS: 55% vs. 90%, P < 0.001 and 3y‐DFS: 45% vs. 75%, P = 0.02). These findings, consistent with our previous observations in TAL1 ‐driven T‐ALL, confirm that the clinico‐biological impact of an oncogene is influenced by the specific mechanism underlying its deregulation.
- 12 June 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (24) , 2903-2913
Surface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL
Refractory and/or relapsing T-cell acute lymphoblastic leukemia (T-ALL) remains a major therapeutic challenge. The pre–T-cell receptor (TCR) pathway has recently emerged as a therapeutic target via LCK inhibition in this context. However, there is a need for simple and quickly assessable biomarkers to predict sensitivity to LCK inhibitors. Moreover, targeting LCK alone by tyrosine kinase inhibitors, such as dasatinib, often results in transient clinical responses, emphasizing the need for efficient combination strategies. Here, we assessed pre-TCR α chain (pTα) surface expression by flow cytometry in a unique series of 50 adult T-ALL patient-derived xenografts (PDXs). We show that cases displaying a cortical phenotype often express high levels of surface pTα (pre-TCR+ T-ALL) and that the latter associates with LCK activation. Furthermore, we show that ectopic interleukin-7 receptor (IL-7R) expression can rescue pre-TCR+ T-ALL from dasatinib cytotoxicity (5 PDXs). We tested whether coinhibition of pre-TCR and IL-7R signaling pathways could be synergetic in pre-TCR+ IL-7R+ T-ALL (11 PDXs). Combination of JAK inhibitors, ruxolitinib or tofacitinib, with dasatinib elicited strong and specific synergy in IL-7R+ pre-TCR+ T-ALL in vitro, including in the relapse setting (4 of 28 patient-derived primary samples). Using 3 adult-PDX models, we show that in vivo treatment with this combination significantly delayed leukemic progression and prolonged survival compared with either monotherapy. This preclinical study thus proposes the use of pTα as a biomarker of LCK-inhibitor sensitivity in T-ALL, and suggests that dual targeting of IL-7R and pre-TCR signaling pathways may be a relevant therapeutic strategy in a substantial proportion of adult T-ALL.
- 12 June 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (24) , 2903-2913
Surface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL
Refractory and/or relapsing T-cell acute lymphoblastic leukemia (T-ALL) remains a major therapeutic challenge. The pre–T-cell receptor (TCR) pathway has recently emerged as a therapeutic target via LCK inhibition in this context. However, there is a need for simple and quickly assessable biomarkers to predict sensitivity to LCK inhibitors. Moreover, targeting LCK alone by tyrosine kinase inhibitors, such as dasatinib, often results in transient clinical responses, emphasizing the need for efficient combination strategies. Here, we assessed pre-TCR α chain (pTα) surface expression by flow cytometry in a unique series of 50 adult T-ALL patient-derived xenografts (PDXs). We show that cases displaying a cortical phenotype often express high levels of surface pTα (pre-TCR+ T-ALL) and that the latter associates with LCK activation. Furthermore, we show that ectopic interleukin-7 receptor (IL-7R) expression can rescue pre-TCR+ T-ALL from dasatinib cytotoxicity (5 PDXs). We tested whether coinhibition of pre-TCR and IL-7R signaling pathways could be synergetic in pre-TCR+ IL-7R+ T-ALL (11 PDXs). Combination of JAK inhibitors, ruxolitinib or tofacitinib, with dasatinib elicited strong and specific synergy in IL-7R+ pre-TCR+ T-ALL in vitro, including in the relapse setting (4 of 28 patient-derived primary samples). Using 3 adult-PDX models, we show that in vivo treatment with this combination significantly delayed leukemic progression and prolonged survival compared with either monotherapy. This preclinical study thus proposes the use of pTα as a biomarker of LCK-inhibitor sensitivity in T-ALL, and suggests that dual targeting of IL-7R and pre-TCR signaling pathways may be a relevant therapeutic strategy in a substantial proportion of adult T-ALL.
- Open Access
- 27 May 2025
- Published by Wiley in HemaSphere
- Vol. 9 (5) , e70154
Oncogenomic profiling in infant–toddler T‐ALL identifies NKX2 family genes as drivers linked to favorable outcomes
T‐cell acute lymphoblastic leukemia (T‐ALL) is a rare and aggressive hematological malignancy primarily affecting adolescents and young adults and is scarce in infants and toddlers under age 3. Unlike B‐ALL, T‐ALL in this young population remains poorly characterized due to limited data and lacks evidence‐based guidelines to help clinicians determine the optimal treatment approach. In this study, we conducted a comprehensive genetic analysis of infant/toddler T‐ALL cases from a French national cohort, utilizing high‐throughput targeted sequencing, optical genome mapping, and RNA sequencing. Genetic analysis revealed the absence of TLX1/3 dysregulation. Instead, we identified a significant prevalence of NKX2 rearrangements ( n = 9, 33%), co‐occurring with MYB alterations ( n = 5/9) or chromothripsis‐like events ( n = 3/9). Additional findings included TAL1/‐like anomalies (30%), STAG2::LMO2 (15%), ETS rearrangements (15%), and rarely, KMT2A rearrangements (7%). Comparative analyses with 245 patients aged 3–18 years, enrolled in the pediatric FRALLE2000T French protocol, underscored the distinct clinical and genetic profiles of infants/toddlers. Despite presenting with higher rates of hyperleukocytosis and slower responses to treatment, they demonstrated comparable survival outcomes to older pediatric patients, with a 5‐year overall survival (OS) rate of 75.4% (95% confidence interval [CI]: 60.0%–94.8%) versus 75.2% (95% CI: 69.8%–81.1%), p = 0.86. Notably, alterations in NKX2 , KMT2A , and STAG2::LMO2 delineated oncogenic subgroups exhibiting a remarkable 100% OS rate, while patients with TAL1 or ETS dysregulation experienced less favorable outcomes. This was further supported by analyses of data from the COG AALL0434 trial, enhancing our understanding of T‐ALL in infants/toddlers. Large‐scale collaborative studies remain essential to confirm these findings and refine treatment strategies.
- 27 May 2025
- Published by Wiley in HemaSphere
- Vol. 9 (5) , e70154
Open AccessOncogenomic profiling in infant–toddler T‐ALL identifies NKX2 family genes as drivers linked to favorable outcomes
T‐cell acute lymphoblastic leukemia (T‐ALL) is a rare and aggressive hematological malignancy primarily affecting adolescents and young adults and is scarce in infants and toddlers under age 3. Unlike B‐ALL, T‐ALL in this young population remains poorly characterized due to limited data and lacks evidence‐based guidelines to help clinicians determine the optimal treatment approach. In this study, we conducted a comprehensive genetic analysis of infant/toddler T‐ALL cases from a French national cohort, utilizing high‐throughput targeted sequencing, optical genome mapping, and RNA sequencing. Genetic analysis revealed the absence of TLX1/3 dysregulation. Instead, we identified a significant prevalence of NKX2 rearrangements ( n = 9, 33%), co‐occurring with MYB alterations ( n = 5/9) or chromothripsis‐like events ( n = 3/9). Additional findings included TAL1/‐like anomalies (30%), STAG2::LMO2 (15%), ETS rearrangements (15%), and rarely, KMT2A rearrangements (7%). Comparative analyses with 245 patients aged 3–18 years, enrolled in the pediatric FRALLE2000T French protocol, underscored the distinct clinical and genetic profiles of infants/toddlers. Despite presenting with higher rates of hyperleukocytosis and slower responses to treatment, they demonstrated comparable survival outcomes to older pediatric patients, with a 5‐year overall survival (OS) rate of 75.4% (95% confidence interval [CI]: 60.0%–94.8%) versus 75.2% (95% CI: 69.8%–81.1%), p = 0.86. Notably, alterations in NKX2 , KMT2A , and STAG2::LMO2 delineated oncogenic subgroups exhibiting a remarkable 100% OS rate, while patients with TAL1 or ETS dysregulation experienced less favorable outcomes. This was further supported by analyses of data from the COG AALL0434 trial, enhancing our understanding of T‐ALL in infants/toddlers. Large‐scale collaborative studies remain essential to confirm these findings and refine treatment strategies.
- Open Access
- 4 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
A metabolic synthetic lethality of phosphoinositide 3-kinase-driven cancer
The deregulated activation of the phosphoinositide 3-kinase (PI3K) pathway is a hallmark of aggressive tumors with metabolic plasticity, eliciting their adaptation to the microenvironment and resistance to chemotherapy. A significant gap lies between the biological features of PI3K-driven tumors and the specific targeting of their vulnerabilities. Here, we explore the metabolic liabilities of PI3K-altered T-cell acute lymphoblastic leukemia (T-ALL), an aggressive hematological cancer with dismal outcomes. We report a metabolic crosstalk linking glutaminolysis and glycolysis driven by PI3K signaling alterations. Pharmaceutical inhibition of mTOR reveals the singular plasticity of PI3K-altered cells toward the mobilization of glutamine as a salvage pathway to ensure their survival. Subsequently, the combination of glutamine degradation and mTOR inhibition demonstrates robust cytotoxicity in PI3K-driven solid and hematological tumors in pre-clinical and clinical settings. We propose a novel therapeutic strategy to circumvent metabolic adaptation and efficiently target PI3K-driven cancer.
- 4 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Open AccessA metabolic synthetic lethality of phosphoinositide 3-kinase-driven cancer
The deregulated activation of the phosphoinositide 3-kinase (PI3K) pathway is a hallmark of aggressive tumors with metabolic plasticity, eliciting their adaptation to the microenvironment and resistance to chemotherapy. A significant gap lies between the biological features of PI3K-driven tumors and the specific targeting of their vulnerabilities. Here, we explore the metabolic liabilities of PI3K-altered T-cell acute lymphoblastic leukemia (T-ALL), an aggressive hematological cancer with dismal outcomes. We report a metabolic crosstalk linking glutaminolysis and glycolysis driven by PI3K signaling alterations. Pharmaceutical inhibition of mTOR reveals the singular plasticity of PI3K-altered cells toward the mobilization of glutamine as a salvage pathway to ensure their survival. Subsequently, the combination of glutamine degradation and mTOR inhibition demonstrates robust cytotoxicity in PI3K-driven solid and hematological tumors in pre-clinical and clinical settings. We propose a novel therapeutic strategy to circumvent metabolic adaptation and efficiently target PI3K-driven cancer.
- Top Cited Papers
- 10 October 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (15) , 1570-1580
NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients
We previously reported a better outcome in adult and pediatric T-cell acute lymphoblastic leukemia (T-ALL) harboring NOTCH1 and/or FBXW7 mutations without alterations of K-N-RAS and PTEN genes. Availability of high-throughput next-generation sequencing (NGS) strategies led us to refine the outcome prediction in T-ALL. Targeted whole-exome sequencing of 72 T-ALL–related oncogenes was performed in 198 adults with T-ALLs in first remission from the GRAALL-2003/2005 protocols and 242 pediatric patients with T-ALLs from the FRALLE2000T. This approach enabled the identification of, to our knowledge, the first NGS-based classifier in T-ALL, categorizing low-risk patients as those with N/F, PHF6, or EP300 mutations, excluding N-K-RAS, PI3K pathway (PTEN, PIK3CA, and PIK3R1), TP53, DNMT3A, IDH1/2, and IKZF1 alterations, with a 5-year cumulative incidence of relapse (CIR) estimated at 21%. Conversely, the remaining patients were classified as high risk, exhibiting a 5-year CIR estimated at 47%. We externally validated this stratification in the pediatric cohort. NGS-based classifier was highly prognostic independently of minimal residual disease (MRD) and white blood cell (WBC) counts, in both adult and pediatric cohorts. Integration of the NGS-based classifier into a comprehensive risk-stratification model, including WBC count at diagnosis and MRD at the end of induction, enabled the identification of an adverse-risk subgroup (25%) with a 5-year CIR estimated at 51%, and a favorable-risk group (32%) with a 5-year CIR estimated at 12%. NGS-based stratification combined with WBC and MRD sharpens the prognostic classification in T-ALL and identifies a new subgroup of patients who may benefit from innovative therapeutic approaches. The GRAALL-2003/2005 studies were registered at www.ClinicalTrials.gov as #NCT00222027 and #NCT00327678.
- 10 October 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (15) , 1570-1580
Top Cited PapersNGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients
We previously reported a better outcome in adult and pediatric T-cell acute lymphoblastic leukemia (T-ALL) harboring NOTCH1 and/or FBXW7 mutations without alterations of K-N-RAS and PTEN genes. Availability of high-throughput next-generation sequencing (NGS) strategies led us to refine the outcome prediction in T-ALL. Targeted whole-exome sequencing of 72 T-ALL–related oncogenes was performed in 198 adults with T-ALLs in first remission from the GRAALL-2003/2005 protocols and 242 pediatric patients with T-ALLs from the FRALLE2000T. This approach enabled the identification of, to our knowledge, the first NGS-based classifier in T-ALL, categorizing low-risk patients as those with N/F, PHF6, or EP300 mutations, excluding N-K-RAS, PI3K pathway (PTEN, PIK3CA, and PIK3R1), TP53, DNMT3A, IDH1/2, and IKZF1 alterations, with a 5-year cumulative incidence of relapse (CIR) estimated at 21%. Conversely, the remaining patients were classified as high risk, exhibiting a 5-year CIR estimated at 47%. We externally validated this stratification in the pediatric cohort. NGS-based classifier was highly prognostic independently of minimal residual disease (MRD) and white blood cell (WBC) counts, in both adult and pediatric cohorts. Integration of the NGS-based classifier into a comprehensive risk-stratification model, including WBC count at diagnosis and MRD at the end of induction, enabled the identification of an adverse-risk subgroup (25%) with a 5-year CIR estimated at 51%, and a favorable-risk group (32%) with a 5-year CIR estimated at 12%. NGS-based stratification combined with WBC and MRD sharpens the prognostic classification in T-ALL and identifies a new subgroup of patients who may benefit from innovative therapeutic approaches. The GRAALL-2003/2005 studies were registered at www.ClinicalTrials.gov as #NCT00222027 and #NCT00327678.
- 29 August 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (9) , 988-1000
Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL
Given the poor outcome of refractory and relapsing T-cell acute lymphoblastic leukemia (T-ALL), identifying prognostic markers is still challenging. Using single nucleotide polymorphism (SNP) array analysis, we provide a comprehensive analysis of genomic imbalances in a cohort of 317 newly diagnosed patients with T-ALL including 135 children and 182 adults with respect to clinical and biological features and outcomes. SNP array results identified at least 1 somatic genomic imbalance in virtually all patients with T-ALL (∼96%). Del(9)(p21) (∼70%) and UPD(9)p21)/CDKN2A/B (∼28%) were the most frequent genomic imbalances. Unexpectedly del(13)(q14)/RB1/DLEU1 (∼14%) was the second most frequent copy number variant followed by del(6)(q15)/CASP8AP2 (∼11%), del(1)(p33)/SIL-TAL1 (∼11%), del(12)(p13)ETV6/CDKN1B (∼9%), del(18)(p11)/PTPN2 (∼9%), del(1)(p36)/RPL22 (∼9%), and del(17)(q11)/NF1/SUZ12 (∼8%). SNP array also revealed distinct profiles of genomic imbalances according to age, immunophenotype, and oncogenetic subgroups. In particular, adult patients with T-ALL demonstrated a significantly higher incidence of del(1)(p36)/RPL22, and del(13)(q14)/RB1/DLEU1, and lower incidence of del(9)(p21) and UPD(9p21)/CDKN2A/B. We determined a threshold of 15 genomic imbalances to stratify patients into high- and low-risk groups of relapse. Survival analysis also revealed the poor outcome, despite the low number of affected cases, conferred by the presence of chromothripsis (n = 6, ∼2%), del(16)(p13)/CREBBP (n = 15, ∼5%) as well as the newly-identified recurrent gain at 6q27 involving MLLT4 (n = 10, ∼3%). Genomic complexity, del(16)(p13)/CREBBP and gain at 6q27 involving MLLT4, maintained their significance in multivariate analysis for survival outcome. Our study thus demonstrated that whole genome analysis of imbalances provides new insights to refine risk stratification in T-ALL. This trial was registered at www.ClinicalTrials.gov as #NCT00222027 and #NCT00327678, and as #FRALLE 2000T trial.
- 29 August 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (9) , 988-1000
Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL
Given the poor outcome of refractory and relapsing T-cell acute lymphoblastic leukemia (T-ALL), identifying prognostic markers is still challenging. Using single nucleotide polymorphism (SNP) array analysis, we provide a comprehensive analysis of genomic imbalances in a cohort of 317 newly diagnosed patients with T-ALL including 135 children and 182 adults with respect to clinical and biological features and outcomes. SNP array results identified at least 1 somatic genomic imbalance in virtually all patients with T-ALL (∼96%). Del(9)(p21) (∼70%) and UPD(9)p21)/CDKN2A/B (∼28%) were the most frequent genomic imbalances. Unexpectedly del(13)(q14)/RB1/DLEU1 (∼14%) was the second most frequent copy number variant followed by del(6)(q15)/CASP8AP2 (∼11%), del(1)(p33)/SIL-TAL1 (∼11%), del(12)(p13)ETV6/CDKN1B (∼9%), del(18)(p11)/PTPN2 (∼9%), del(1)(p36)/RPL22 (∼9%), and del(17)(q11)/NF1/SUZ12 (∼8%). SNP array also revealed distinct profiles of genomic imbalances according to age, immunophenotype, and oncogenetic subgroups. In particular, adult patients with T-ALL demonstrated a significantly higher incidence of del(1)(p36)/RPL22, and del(13)(q14)/RB1/DLEU1, and lower incidence of del(9)(p21) and UPD(9p21)/CDKN2A/B. We determined a threshold of 15 genomic imbalances to stratify patients into high- and low-risk groups of relapse. Survival analysis also revealed the poor outcome, despite the low number of affected cases, conferred by the presence of chromothripsis (n = 6, ∼2%), del(16)(p13)/CREBBP (n = 15, ∼5%) as well as the newly-identified recurrent gain at 6q27 involving MLLT4 (n = 10, ∼3%). Genomic complexity, del(16)(p13)/CREBBP and gain at 6q27 involving MLLT4, maintained their significance in multivariate analysis for survival outcome. Our study thus demonstrated that whole genome analysis of imbalances provides new insights to refine risk stratification in T-ALL. This trial was registered at www.ClinicalTrials.gov as #NCT00222027 and #NCT00327678, and as #FRALLE 2000T trial.
- 20 March 2024
- Published by Springer Nature in Nature
- Vol. 628 (8008) , 620-629
Role of IL-27 in Epstein–Barr virus infection revealed by IL-27RA deficiency
Epstein–Barr virus (EBV) infection can engender severe B cell lymphoproliferative diseases1,2. The primary infection is often asymptomatic or causes infectious mononucleosis (IM), a self-limiting lymphoproliferative disorder3. Selective vulnerability to EBV has been reported in association with inherited mutations impairing T cell immunity to EBV4. Here we report biallelic loss-of-function variants in IL27RA that underlie an acute and severe primary EBV infection with a nevertheless favourable outcome requiring a minimal treatment. One mutant allele (rs201107107) was enriched in the Finnish population (minor allele frequency = 0.0068) and carried a high risk of severe infectious mononucleosis when homozygous. IL27RA encodes the IL-27 receptor alpha subunit5,6. In the absence of IL-27RA, phosphorylation of STAT1 and STAT3 by IL-27 is abolished in T cells. In in vitro studies, IL-27 exerts a synergistic effect on T-cell-receptor-dependent T cell proliferation7 that is deficient in cells from the patients, leading to impaired expansion of potent anti-EBV effector cytotoxic CD8+ T cells. IL-27 is produced by EBV-infected B lymphocytes and an IL-27RA–IL-27 autocrine loop is required for the maintenance of EBV-transformed B cells. This potentially explains the eventual favourable outcome of the EBV-induced viral disease in patients with IL-27RA deficiency. Furthermore, we identified neutralizing anti-IL-27 autoantibodies in most individuals who developed sporadic infectious mononucleosis and chronic EBV infection. These results demonstrate the critical role of IL-27RA–IL-27 in immunity to EBV, but also the hijacking of this defence by EBV to promote the expansion of infected transformed B cells.
- 20 March 2024
- Published by Springer Nature in Nature
- Vol. 628 (8008) , 620-629
Role of IL-27 in Epstein–Barr virus infection revealed by IL-27RA deficiency
Epstein–Barr virus (EBV) infection can engender severe B cell lymphoproliferative diseases1,2. The primary infection is often asymptomatic or causes infectious mononucleosis (IM), a self-limiting lymphoproliferative disorder3. Selective vulnerability to EBV has been reported in association with inherited mutations impairing T cell immunity to EBV4. Here we report biallelic loss-of-function variants in IL27RA that underlie an acute and severe primary EBV infection with a nevertheless favourable outcome requiring a minimal treatment. One mutant allele (rs201107107) was enriched in the Finnish population (minor allele frequency = 0.0068) and carried a high risk of severe infectious mononucleosis when homozygous. IL27RA encodes the IL-27 receptor alpha subunit5,6. In the absence of IL-27RA, phosphorylation of STAT1 and STAT3 by IL-27 is abolished in T cells. In in vitro studies, IL-27 exerts a synergistic effect on T-cell-receptor-dependent T cell proliferation7 that is deficient in cells from the patients, leading to impaired expansion of potent anti-EBV effector cytotoxic CD8+ T cells. IL-27 is produced by EBV-infected B lymphocytes and an IL-27RA–IL-27 autocrine loop is required for the maintenance of EBV-transformed B cells. This potentially explains the eventual favourable outcome of the EBV-induced viral disease in patients with IL-27RA deficiency. Furthermore, we identified neutralizing anti-IL-27 autoantibodies in most individuals who developed sporadic infectious mononucleosis and chronic EBV infection. These results demonstrate the critical role of IL-27RA–IL-27 in immunity to EBV, but also the hijacking of this defence by EBV to promote the expansion of infected transformed B cells.